Svetlana A. Orlova

Intermediate results of the PERFECTION observational study in a population of patients with metastatic, persistent and recurrent cervical cancer

Valeriya V. Saevets, Nikita K. Kuzmin, Natalia Ponomareva, Tatiana V. Krashikhina et autres

Background. Cervical cancer (CC) is among the four most common malignancies among the female population. For a long time, platinum-based chemotherapy was the standard of care and practically the only option available. However, treatment outcomes for patients with metastatic and recurrent CC …

ru, cz, us (code pays fourni par la source)

Atezolizumab and nab-paclitaxel for advanced triple-negative breast cancer in real-world practice

Inna P Gan'shina, Елена Владимировна Артамонова, Ярослав Андреевич Жуликов, M. V. Koroleva et autres

Introduction. Advances in molecular biology and biotechnology have enhanced the understanding of triple-negative breast cancer (TNBC) biology and facilitated the identification of patient subgroups that may potentially benefit from novel therapeutic approaches. Objective. The aim of this study is to evaluate the …

ru, cz, us (code pays fourni par la source)

Interim results analysis of the PERFECTION observational study in patients with metastatic non-small cell lung cancer

Константин Константинович Лактионов, Mikhail Yu. Fedyanin, Daniil Stroyakovskiy, Aishat R. Iasieva et autres

Aim. To evaluate the efficacy and safety profile of the pembrolizumab biosimilar, Pembroria, in patients with advanced lung cancer in routine clinical practice. Materials and methods. The patients eligible for pembrolizumab therapy based on standard clinical indications and without contraindications participated in …

ru, id, gb, cz (code pays fourni par la source)

Myocardial remodeling in wistar rats with renal dysfunction fed a high-salt diet

M. H. Hasun, Galina T. Ivanova, Marina Parastaeva, Evdokia O. Bogdanova et autres

BACKGROUND. Dietary adjustment is an important point in the treatment of chronic kidney disease (CKD). However, at present, the effect of a diet with a high NaCl content on the state of the cardiovascular system in patients with early stages of CKD …

ru (code pays fourni par la source)

Effectiveness and safety of empegfilgrastim (Extimia®) in patients with solid tumors receiving cytotoxic therapy: final results of the DEFENDOR study

A. V. Snegovoy, И. Б. Кононенко, И. М. Радюкова, Svetlana A. Orlova et autres

Aim. To evaluate the effectiveness and safety of Extimia® (empegfilgrastim, JSC "BIOCAD") in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia (FN) and infections caused by FN in patients with solid tumors receiving myelosuppressive therapy. Materials and methods. The …

ru (code pays fourni par la source)

Safety of Pembroria® during non-medical switching from Keytruda® in patients with advanced malignant neoplasms of various localizations: the REFLECTION real-world study

Е. Л. Чойнзонов, А. А. Феденко, Natalia A. Falaleeva, Т. В. Андреева et autres

Background. Post-registration observational studies with switching therapy from the original drug to a biosimilar for non-medical indications allow us to assess the safety and effectiveness of this type of switching in real clinical practice. Aim. Evaluation of the safety and effectiveness of …

ru, gb (code pays fourni par la source)

Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia

Кристина Вячеславовна Орлова, Mikhail Yu. Fedyanin, Konstantin E. Simanenkov, Aleksandr S. Dergunov et autres

Background. Prior to the introduction of new agents — immune checkpoint inhibitors — for inoperable and/or metastatic melanoma (IMM), chemotherapy outcomes were generally poor. The median (Me) overall survival (OS) in IMM was no more than 6-9 months, and the Me of …

id, ru, us, gb, by (code pays fourni par la source)

Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study

Ekaterina Nesterova, Aleksandra F. Saydullaeva, Dmitry G. Sherstnev, Tatiana V. Shelekhova et autres

Aim. To evaluate the effectiveness and safety of Extimia® BIOCAD (international non-proprietary name: empegfilgrastim) to reduce the incidence and duration of neutropenia, the incidence of febrile neutropenia (FN) and infections associated with FN in patients with lymphoproliferative diseases receiving myelosuppressive therapy. Materials …

ru (code pays fourni par la source)

The minimally invasive method for treatment of stress urinary incontinence in women

Vera E. Balan, Elena V. Tikhomirova, М. А. Чечнева, О.V. Kapitanova et autres

Urinary incontinence is a complex medical and social problem. Surgical methods designed to treat stress urinary incontinence are expensive and have a number of complications, and existing alternative surgical methods have been ineffective and caused complications due to the very nature of …

Transcatheter aortic valve implantation in patient with Heyde’s syndrome

K. V. Legostaeva, E. A. Vorobyev, Svetlana A. Orlova, N. D. Grigoreva et autres

Clinical case of an 85-year-old patient with Heid’s syndrome is being reported: recurrent gastrointestinal bleeding due to angiodysplasia of the stomach and intestines in combination with acquired destruction of large von Willebrand factor multimers in severe aortic stenosis. Actually it remains difficult …

Myocardial effects of a low-protein diet in experimental kidney dysfunction

Olga Beresneva, Marina Parastaeva, Galina T. Ivanova, Mikhail Zaraiski et autres

THE AIM: to evaluate the effect of low protein diet supplemented with ketosteril on morphological and epigenomic changes in the myocardium of Wistar rats with simulated kidney dysfunction . MATERIALS AND METHODS. The work was performed on male Wistar rats subjected to …

ru (code pays fourni par la source)

Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study

Ekaterina Nesterova, Aleksandra F. Saydullaeva, Dmitry G. Sherstnev, Tatiana V. Shelekhova et autres

Aim. To assess effectiveness and safety of Extimia BIOCAD (INN: empegfilgrastim) used to decrease the rate and duration of neutropenia, the rate of febrile neutropenia and infections that manifest in febrile neutropenia in patients with lymphoproliferative diseases who receive myelosuppressive therapy. Materials …

ru, ua (code pays fourni par la source)